Letolizumab

Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]

Letolizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized (from mouse)
Targettumor necrosis factor-related activation protein
Clinical data
Other namesBMS-986004
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1734H2688N466O538S10
Molar mass38991.90 g·mol−1

This drug was developed by Bristol-Myers Squibb.[3]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.